A detailed history of Srs Capital Advisors, Inc. transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Srs Capital Advisors, Inc. holds 782 shares of NBIX stock, worth $97,750. This represents 0.01% of its overall portfolio holdings.

Number of Shares
782
Previous 782 -0.0%
Holding current value
$97,750
Previous $107,000 15.89%
% of portfolio
0.01%
Previous 0.01%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 06, 2024

BUY
$130.86 - $143.19 $96,705 - $105,817
739 Added 1718.6%
782 $107,000
Q4 2023

Feb 06, 2024

SELL
$106.07 - $132.76 $318 - $398
-3 Reduced 6.52%
43 $5,000
Q3 2023

Nov 14, 2023

BUY
$94.02 - $117.1 $846 - $1,053
9 Added 24.32%
46 $5,000
Q2 2023

Aug 14, 2023

SELL
$89.53 - $104.87 $805 - $943
-9 Reduced 19.57%
37 $3,000
Q3 2022

Nov 03, 2022

BUY
$92.03 - $107.81 $828 - $970
9 Added 24.32%
46 $5,000
Q1 2022

May 12, 2022

BUY
$72.45 - $94.81 $2,680 - $3,507
37 New
37 $3,000

Others Institutions Holding NBIX

About NEUROCRINE BIOSCIENCES INC


  • Ticker NBIX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 95,639,296
  • Market Cap $12B
  • Description
  • Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...
More about NBIX
Track This Portfolio

Track Srs Capital Advisors, Inc. Portfolio

Follow Srs Capital Advisors, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Srs Capital Advisors, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Srs Capital Advisors, Inc. with notifications on news.